Canton Strategic Holdings (CNTN) Interest Expenses (2020 - 2025)
Canton Strategic Holdings' (CNTN) quarterly Interest Expenses came in at $4065.0 in Q4 2025, up 436.28% YoY from $758.0 in Q4 2024, and down 57.87% on a QoQ basis from $9648.0 in Q3 2025.
Canton Strategic Holdings (CNTN) Interest Expenses (2020 - 2025) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Interest Expenses data on file, last reported at $4065.0 in Q4 2025.
- Quarterly Interest Expenses rose 436.28% year-over-year to $4065.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $19874.0 (up 13.86% YoY) and the FY2025 annual result came in at $5.1 million, down 50.15% from the prior year.
- Interest Expenses slipped to $4065.0 in Q4 2025, from $9648.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.6 million in Q1 2022 to a low of -$1.6 million in Q4 2022.
- A 5-year average of $47998.2 and a median of $6138.0 in 2023 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 979.69% in 2022, down 708.14% in 2022.
- Tracing CNTN's Interest Expenses over 5 years: stood at $258000.0 in 2021, then plunged by 708.14% to -$1.6 million in 2022, then soared by 100.02% to $354.0 in 2023, then surged by 114.12% to $758.0 in 2024, then surged by 436.28% to $4065.0 in 2025.
- The last three Interest Expenses figures came in at $4065.0 (Q4 2025), $9648.0 (Q3 2025), and $6161.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Canton Strategic Holdings | 419.57 Mn | 419.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,065.00 |
| Dec 31, 2025 | 4,065.00 |
| Sep 30, 2025 | 9,648.00 |
| Sep 30, 2025 | 9,648.00 |
| Jun 30, 2025 | 6,161.00 |
| Jun 30, 2025 | 6,161.00 |
| Mar 31, 2025 | 8,471.00 |
| Mar 31, 2025 | 8,471.00 |
| Dec 31, 2024 | 758.00 |
| Dec 31, 2024 | 758.00 |
| Sep 30, 2024 | 3,009.00 |
| Sep 30, 2024 | 3,009.00 |
| Jun 30, 2024 | 5,217.00 |
| Jun 30, 2024 | 5,217.00 |
| Mar 31, 2024 | 4,700.00 |
| Mar 31, 2024 | 4,700.00 |
| Dec 31, 2023 | 354.00 |
| Dec 31, 2023 | 354.00 |
| Sep 30, 2023 | 3,496.00 |
| Sep 30, 2023 | 3,496.00 |